Existing partner, Endeavour Cells ApS provides capital increase to Cell2Cure ApS and own thereby own 51% of the company.
In collaboration with Endeavour Cells, the capital increase will be used to further develop Cell2Cure’s stem cell products both technically, clinically and commercially.
Cell2Cure’s products will be made market-ready to promote treatment with stem cells within a number of diseases – both nationally and abroad.
In addition to the capital injected, the collaboration with Endeavour Cells includes an agreement on milestone payments and possible continued financing of Cell2Cure’s activities within a 5-year time frame.
In connection with the capital increase, owner of Endeavour Cells ApS, Anders Østergaard, will become the new Chairman of the Board in Cell2Cure.
Anders Østergaard, CEO Endeavour Invest:
“We are convinced that stem cells in the long term will provide a significant contribution to the treatment of many different disorders and diseases. Endeavour Cells is therefore pleased to continue the collaboration and with the capital increase, we ensure Cell2Cure’s is able to focus on the important and promising technical and clinical work in the coming years.”
Jens Kastrup, CEO & Clinical Director, Cell2Cure:
“Cell2Cure is pleased with the trust that Endeavour Cells shows in our team and stem cell concept by expanding the collaboration with this capital injection. The commercial and organisational expertise that is also added through the expansion will be of great importance for Cell2Cure’s opportunities to expand and further develop stem cell technology and stem cell treatment for many different diseases and patient groups in need of new treatment concepts.“
